9/25/2023-Unusual Options Activity In KE

9/25/2023-Unusual Options Activity In KE

KE Holdings, Inc. engages in the provision of an integrated online and offline platform for housing transactions and services through its subsidiaries. It operates under the following segments: Existing Home Transaction Services, New Home Transaction Services, Home Renovation and Furnishing, and Emerging and Other Services. The Existing Home Transaction Services segment provides services in existing home market. The New Home Transaction Services segment consists of new home transaction services in new home market. The Home Renovation and Furnishing segment provides a one-stop solution to give housing customers access to a comprehensive range of home renovation and furnishing, ranging from interior design, renovation, re-modeling, furnishing, supplies, to after-sales maintenance and repair. The Emerging and Other Services segment includes rental property management service business, financial service business, and other newly developed businesses. The company was founded by Hui Zou, Yongdong Peng, and Shan Yi Gang on July 6, 2018 and is headquartered in Beijing, China.

9/25/2023-Unusual Options Activity In MRVL

9/25/2023-Unusual Options Activity In MRVL

Marvell Technology, Inc. is an American company, headquartered in Santa Clara, California, which develops and produces semiconductors and related technology. Founded in 1995, the company had more than 7,000 employees as of 2023, with over 10,000 patents worldwide, and an annual revenue of $5.9 billion for fiscal 2023.

9/20/2023-Unusual Options Activity In VKTX

9/20/2023-Unusual Options Activity In VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

9/19/2023-Unusual Options Activity In WW

9/19/2023-Unusual Options Activity In WW

WW International, Inc. provides weight management products and services worldwide. It offers a range of nutritional, activity, behavioral, and lifestyle tools and approaches products and services. The company also provides various digital subscription products to wellness and weight management business, which provide interactive and personalized resources that allow users to follow its weight management program through its app and web-based platform, including personal coaching and digital products; and allows members to inspire and support each other by sharing their experiences with other people on weight loss and weight management journeys.

9/19/2023-Unusual Options Activity In EBIX

9/19/2023-Unusual Options Activity In EBIX

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions.